A new UCLA Health Jonsson Comprehensive Cancer Center study suggests that the way immune cells are organized inside melanoma ...

During a live event, participants discuss barriers to access and bridging strategies for tumor-infiltrating lymphocytes in ...

Earlier this year, the largest trial to date on cancer blood tests failed to reach its primary objective. Oncologists haven't ...

While immunotherapy is the primary driver of skin sensitivity in melanoma care, Wong issued a "public service announcement" ...

As Skin Cancer Awareness Month approaches this May, SkinScan Ireland and Waterford-based GP Dr David Brennan are encouraging people across Ireland to take a more proactive approach to protecting their ...

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit ...

By AARON BEARD, AP Basketball Writer. Famed ESPN broadcaster Dick Vitale is facing another battle with cancer. Related Articles. In Miami, soccer balls are turned into one-of-a-ki ...

A closely watched clinical trial testing a new two-drug combination against metastatic uveal melanoma, the deadliest form of ...

Servier $210 million bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as the drug has hit the mark in a phase 2/3 that could form the basis of regulatory filings later this ...

IDEAYA Biosciences (IDYA) stock jumped 26% after its eye cancer drug combo doubled progression-free survival in a Phase 2/3 trial versus standard care.

A phase 2/3 trial of Ideaya Biosciences and Servier’s eye cancer candidate has hit its primary endpoint, teeing up a filing for accelerated FDA approval in the second half of th ...

IDEAYA Biosciences and French pharma company Servier said ​on Monday their combination drug for a type of eye cancer met the ‌main goal of a mid-to-late-stage trial, sending the U.S. biotech's shares ...